March 21, 2019

Biogen and Eisai to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab

SCHLIEREN / ZURICH, SWITZERLAND – March 21, 2019 – Neurimmune today informed that Biogen and Eisai decided to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab in Alzheimer’s disease. Neurimmune has partnered Aducanumab with Biogen in 2007. The independent data monitoring committee advised that the trials were unlikely to meet their primary endpoint upon completion. This recommendation was not based on safety concerns. Link to the Biogen media release >>

 “This outcome is very disappointing for patients with Alzheimer's disease and their families as well as for the entire Neurimmune team", said Roger Nitsch, Neurimmune’s CEO & President. "Despite this setback in the quest for a cure for Alzheimer's disease, Neurimmune remains committed to find solutions for neurodegenerative and other severe diseases.”

Neurimmune's preclinical and clinical pipeline includes drug candidates at various development stages for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, cardiomyopathy, type 2 diabetes, as well as programs in cognitive dysfunction and attention disorders. Neurimmune’s R&D programs are based on its unique reverse translational medicine technology which enables the translation of DNA from human immune cells into next-generation antibodies.”


About Neurimmune

Neurimmune is a Swiss clinical stage biotech company translating human immune memory into therapeutics. Neurimmune’s pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages. Aducanumab, an investigational treatment for Alzheimer’s disease has been partnered with Biogen in 2007. Rights in antibodies BIIB054 for Parkinson’s disease and BIIB076 for Alzheimer’s disease were acquired by Biogen. Neurimmune partnered with TVM and Eli Lilly’s Chorus unit to advance an antibody for the treatment of amyotrophic lateral sclerosis. Neurimmune’s pipeline includes human antibody programs for cardiomyopathy, type-2 diabetes as well as a small-molecule program for cognitive dysfunction.


Contact Neurimmune
Fabian Buller, PhD
Chief Business Officer
+41 44 755 46 46